HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma: Suberoylanilide hydroxamic acid (SAHA), an HDAC inhibitor, received FDA approval for treatment of cutaneous T-cell lymphoma (CTCL) [30].